Hi-Tech Chemo Equip Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 03-01-2025
- Paid Up Capital ₹ 5.00 M
as on 03-01-2025
- Company Age 19 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.48 Cr
as on 03-01-2025
- Satisfied Charges ₹ 3.73 Cr
as on 03-01-2025
- Revenue -3.07%
(FY 2021)
- Profit -2958.61%
(FY 2021)
- Ebitda -274.57%
(FY 2021)
- Net Worth -344.19%
(FY 2021)
- Total Assets -11.32%
(FY 2021)
About Hi-Tech Chemo Equip
The Company is engaged in the Machinery And Equipment Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 5.00 M.
The company currently has active open charges totaling ₹1.48 Cr. The company has closed loans amounting to ₹3.73 Cr, as per Ministry of Corporate Affairs (MCA) records.
Ibrahim Kankanady and Sanjay Phegade serve as directors at the Company.
- CIN/LLPIN
U28900MH2005PTC151202
- Company No.
151202
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 Feb 2005
- Date of AGM
18 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Hi-Tech Chemo Equip?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ibrahim Kankanady  | Director | 10-Feb-2005 | Current |
| Sanjay Phegade | Director | 10-Feb-2005 | Current |
Financial Performance of Hi-Tech Chemo Equip.
Hi-Tech Chemo Equip Private Limited, for the financial year ended 2021, experienced Minor drop in revenue, with a 3.07% decrease. The company also saw a substantial fall in profitability, with a 2958.61% decrease in profit. The company's net worth observed a substantial decline by a decrease of 344.19%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Hi-Tech Chemo Equip?
In 2021, Hi-Tech Chemo Equip had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 19 Mar 2022 | ₹4.80 M | Open |
Others Creation Date: 18 Dec 2013 | ₹1.00 Cr | Open |
Others Creation Date: 01 Jan 2022 | ₹5.00 M | Satisfied |
How Many Employees Work at Hi-Tech Chemo Equip?
Hi-Tech Chemo Equip has a workforce of 16 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Hi-Tech Chemo Equip, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Hi-Tech Chemo Equip's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
